Table 2.
Medications on Admission and at Discharge, and Loop Diuretic Dose
| Medication | Total (n=233) | Non‐WRF (n=185) | 1y‐WRF (n=48) | P Value |
|---|---|---|---|---|
| Admission, % | ||||
| ACE inhibitor or ARB | 61.8 | 59.5 | 70.8 | 0.1484 |
| β‐blocker | 30.5 | 29.7 | 33.3 | 0.6289 |
| Loop diuretic | 50.2 | 49.2 | 54.2 | 0.5388 |
| MR blocker | 22.8 | 22.7 | 22.9 | 0.9749 |
| Ca channel blocker | 33.9 | 31.9 | 41.7 | 0.2024 |
| Statin | 29.2 | 27.6 | 35.4 | 0.2865 |
| Discharge, % | ||||
| ACE inhibitor or ARB | 91.9 | 91.9 | 91.7 | 0.9595 |
| β‐blocker | 57.9 | 57.8 | 58.3 | 0.9506 |
| Loop diuretic | 85.8 | 83.8 | 93.8 | 0.0776 |
| MR blocker | 38.2 | 35.1 | 50.0 | 0.0589 |
| Ca channel blocker | 27.0 | 26.0 | 31.3 | 0.4610 |
| Loop diuretic dose, mg | ||||
| On admission | 18.9±26.4 | 19.1±24.0 | 18.1±22.1 | 0.7579 |
| At discharge | 31.8±24.2 | 31.7±24.8 | 31.9±22.1 | 0.9372 |
| At 1 y after discharge | 34.9±25.8 | 33.7±26.4 | 39.8±23.2 | 0.1027 |
| Dose increased | 3.18±19.9 | 1.95±19.7 | 7.92±19.8 | 0.0464 |
Dose increased refers to an increase between discharge and 1 y afterwards. ACE indicates angiotensin‐converting enzyme; ARB, angiotensin receptor blocker; Ca, calcium; MR, mineralocorticoid receptor; 1y‐WRF, worsening of renal function during the year after discharge.